Nine neurodegenerative diseases are caused by expanded polyglutamine (polyQ) tracts in different proteins, such as huntingtin in Huntington's disease and ataxin 3 in spinocerebellar ataxia type 3 (SCA3) 1,2 . Age at onset of disease decreases with increasing polyglutamine length in these proteins and the normal length also varies 3 . PolyQ expansions drive pathogenesis in these diseases, as isolated polyQ tracts are toxic, and an N-terminal huntingtin fragment comprising exon 1, which occurs in vivo as a result of alternative splicing 4 , causes toxicity. Although such mutant proteins are prone to aggregation 5 , toxicity is also associated with soluble forms of the proteins 6 . The function of the polyQ tracts in many normal cytoplasmic proteins is unclear. One such protein is the deubiquitinating enzyme ataxin 3 (refs 7, 8), which is widely expressed in the brain 9,10 . Here we show that the polyQ domain enables wild-type ataxin 3 to interact with beclin 1, a key initiator of autophagy 11 . This interaction allows the deubiquitinase activity of ataxin 3 to protect beclin 1 from proteasome-mediated degradation and thereby enables autophagy. Starvation-induced autophagy, which is regulated by beclin 1, was particularly inhibited in ataxin-3-depleted human cell lines and mouse primary neurons, and in vivo in mice. This activity of ataxin 3 and its polyQ-mediated interaction with beclin 1 was competed for by other soluble proteins with polyQ tracts in a length-dependent fashion. This competition resulted in impairment of starvation-induced autophagy in cells expressing mutant huntingtin exon 1, and this impairment was recapitulated in the brains of a mouse model of Huntington's disease and in cells from patients. A similar phenomenon was also seen with other polyQ disease proteins, including mutant ataxin 3 itself. Our data thus describe a specific function for a wild-type polyQ tract that is abrogated by a competing longer polyQ mutation in a disease protein, and identify a deleterious function of such mutations distinct from their propensity to aggregate.
the level of the autophagy substrate, p62 (Extended Data Fig. 1b, c) . Ataxin 3 knockdown decreased the number of autophagosomes and autolysosomes scored with the reporter mTagRFP-mWasabi-LC3, consistent with impaired autophagosome formation (Extended Data Fig. 1d ).
The decrease in autophagosome biogenesis following ataxin 3 knockdown was associated with a decrease in beclin 1 (Fig. 1c ). The phosphatidylinositol 3-phosphate (PtdIns3P) formed by the complex between beclin 1 and the phosphatidylinositol 3 kinase VPS34 is particularly important for inducing autophagy (LC3-II formation in BafA1-treated cells) after nutrient depletion, and such defects are seen in cells with monoallelic deletion of the gene encoding beclin 1 (becn1) 11, 17, 18 . Ataxin-3-depleted cells cultured in starvation medium showed a decrease in PtdIns3P-positive structures, characteristic of beclin 1-depletion 18 (Extended Data Fig. 1e ). In both fed and starved conditions, loading back exogenous PtdIns3P to ataxin-3-depleted cells increased LC3 vesicle numbers to levels comparable to control cells (Extended Data Fig. 2a, b ). Ataxin 3 overexpression increased the number of puncta positive for the PtdIns3P-binding autophagy effector WIPI2, which binds to PtdIns3P at autophagy initiation membranes 19, 20 . This effect was reversed when ataxin 3 overexpressing cells were treated with the phosphatidylinositol 3 kinase inhibitor wortmannin (Extended Data Fig. 2c ). After mice were starved, livers depleted of ataxin 3 failed to upregulate beclin 1 or LC3-II ( Fig. 1d , e, Extended Data Fig. 2d ) and showed increased p62 levels (Extended Data Fig. 2e , f), compared to wild-type livers. Therefore, ataxin 3 knockdown decreased beclin 1 levels, which could explain the decrease in PtdIns3P and consequent impairment in autophagosome biogenesis.
As ataxin 3 interacted with beclin 1 (Fig. 2a ), we tested whether the deubiquitinase activity of ataxin 3 protected beclin 1 against proteasomal degradation. Beclin 1 levels declined more in ataxin-3-depleted cells than in controls after inhibition of protein synthesis, suggesting that depletion of ataxin 3 accelerated beclin 1 turnover (Extended Data Fig. 3a ). Beclin 1 levels were restored in ataxin 3 knockdown cells treated with a proteasome inhibitor (Extended Data Fig. 3b ) and when ataxin-3-depleted cells were transfected with wildtype ataxin 3 but not with a ubiquitin protease-dead mutant (C14A; Extended Data Fig. 3c ). Under proteasome inhibition, ubiquitination of endogenous beclin 1 was increased when ataxin 3 was knocked down (Extended Data Fig. 3d ), and recombinant ataxin 3 but not the protease-dead C14A mutant deubiquitinated beclin 1 in vitro (Fig. 2b , Extended Data Fig. 3e, f showing beclin 1 selectivity). The percentage of cells containing mutant huntingtin exon 1 aggregates correlates with levels of this protein and decreases when autophagy is induced 12 . Consistent with autophagy induction, overexpression of wild-type (but not C14A) ataxin 3 decreased the percentage of such mutant huntingtinexpressing cells that contained aggregates (Extended Data Fig. 3g ).
Our mass spectrometry analysis and others 21 suggest that lysine 402 of beclin 1 was modified with a lysine 48 (K48) ubiquitin chain, a signal for proteasomal degradation (Fig. 2c , Extended Data Fig. 4a, b ). Lysine 402 in the evolutionary conserved domain (ECD) of beclin 1 is conserved in fish, mice and humans (Fig. 2c ). K48-linked beclin 1 polyubiquitination was increased by depletion of ataxin 3, and mutation of lysine 402 to arginine (K402R) decreased K48-linked beclin 1 polyubiquitination, confirming that K402 is a site for this modification (Fig. 2d ). Consequently, K402R beclin 1 was more abundant than wildtype beclin 1 in cells, and levels of K402 beclin 1 did not increase further after treatment with proteasome inhibitors (Extended Data Fig. 4c ). Ataxin 3 expression in HeLa cells increased wild-type beclin 1 levels and did not increase levels of beclin 1 K402R (Extended Data Fig. 4d ). This result is consistent with the finding that cells overexpressing K402R beclin 1 show more autophagy than those overexpressing the wild-type protein (Extended Data Fig. 4d ).
Deletion of the polyQ domain from ataxin 3 greatly reduced its binding to beclin 1 (Fig. 3a) , and an isolated polyQ stretch was sufficient to bind beclin 1 (Fig. 3b) . Thus, the polyQ domain is important for the ataxin 3-beclin 1 interaction, but is not the only binding domain. The beclin l ECD interacted with ataxin 3 ( Fig. 3c ) and also bound the polyQ tract alone (Extended Data Fig. 5a ), suggesting that the ECD of beclin 1 contained polyQ-binding domains, consistent with structural docking models revealing two highly scored polyQ-binding pockets in the beclin 1 ECD ( Fig. 3d , Extended Data Fig. 5b-e ). As some binding was observed with beclin 1 lacking the ECD, other domains of beclin 1 may also interact with ataxin 3.
GFP-tagged isolated polyQ tracts could bind to beclin 1, and longer stretches (Q81) bound beclin 1 more strongly than shorter tracts (Q35) ( Fig. 4a ). Remarkably, beclin 1 K48-polyubiquitination was increased in cells overexpressing GFP-Q35 compared with those expressing empty GFP, and was increased even further by GFP-Q81 overexpression ( Fig. 4a) , consistent with a model in which these constructs compete with the ataxin 3 polyQ stretch that enables binding and subsequent deubiquitination of beclin 1. Indeed, overexpression of GFP-polyQ constructs decreased ataxin 3-beclin 1 binding ( Fig. 4b ). GFP-Q35 (which does not aggregate under our conditions) decreased beclin 1 levels (Extended Data Fig. 6a ), impaired starvation-induced autophagy (Extended Data Fig. 6a, d, e ) and increased p62 levels in starved cells (Extended Data Fig. 6b ). No change in the number of LC3-II vesicles was observed when the Q35 tract was expressed in beclin-1-depleted cells (Extended Data Fig. 6c -e) and the inhibitory effect of Q35 on beclin 1 levels and autophagy in beclin-1-expressing cells was reversed by ataxin 3 overexpression (Extended Data Fig. 6a ), compatible with a model in which Q35 impairs the control of beclin 1 levels by ataxin 3.
A wild-type (Q17) huntingtin fragment (N-terminal 350 residues) bound to beclin 1, and this interaction was largely lost when the polyQ stretch was deleted (Extended Data Fig. 7a ). Furthermore, mutant polyQ-expanded, full-length huntingtin competed with wildtype ataxin 3 for beclin 1 binding (Extended Data Fig. 7b ). To test the general principle on autophagy, we used an N-terminal exon 1 fragment to exclude any confounding effects of the huntingtin C terminus on autophagy 22 . In stable-inducible HEK293 cells expressing wild-type (Q23) and mutant (Q74) huntingtin exon 1 at similar levels (where there was no overt toxicity or aggregation (< 1%) during the experiment), we observed lower beclin 1 levels and impaired starvation-induced autophagy after switching on the huntingtin transgene (Extended Data Fig. 7c-e ). These effects were more pronounced in cells expressing the Q74 mutant. As these phenomena occur in both wild-type Q23-huntingtin-expressing cells and Q35-expressing cells, they cannot be explained simply by sequestration of beclin 1 into aggregates 23 .
Next, we studied cell lines derived from the striatum, the brain region most sensitive to the Huntington's disease mutation, from heterozygous mutant huntingtin (Q7/Q111) and matched wild-type huntingtin knock-in mice (Q7/Q7) both humanized for huntingtin exon 1 (ref. 24) . Mutant huntingtin (Q7/Q111) striatum-derived cells had lower beclin 1 levels and defects in starvation-induction of WIPI2 puncta and LC3-II levels, compared to wild-type (Q7/Q7) cells (Extended Data Fig. 8a -c). Likewise, brains from young mutant huntingtin exon 1 transgenic mice, in which there is minimal overt aggregation (Extended Data Fig. 8d ), showed decreased beclin 1 levels in starving conditions, failed to upregulate LC3-II under starvation, and had increased p62 levels compared to wild-type littermate brains ( Fig. 4c, d , Extended Data Fig. 8e -g).
We then tested whether this mechanism applied to mutant ataxin 3, as decreased beclin 1 levels are seen in rodent models of SCA3 (ref. 25) . Expansion of the polyQ domain in ataxin 3 decreased its deubiquitinase activity towards beclin 1 (Extended Data Fig. 9a ). Transfecting expanded ataxin 3 Q84 into ataxin 3 knockdown cells partially rescued the number of LC3 puncta but was not as effective as wild-type ataxin 3 Q28 (Extended Data Fig. 9b , c), consistent with the decreased deubiquitinase activity of the mutant protein. However, the polyQdeleted ataxin 3 did not rescue the number of LC3 puncta (Extended Data Fig. 9b , c). When overexpressed in cells, Q84 mutant ataxin 3 interacted more strongly with beclin 1 than did wild-type ataxin 3, and this increased interaction was associated with increased beclin 1 K48 polyubiquitination, while no obvious change was observed in beclin 1 K63 polyubiquitination (Extended Data Fig. 9d ). Thus, the longer polyQ stretches in mutant ataxin 3 bind beclin 1 more strongly than wild-type ataxin 3, but the mutant protein also has decreased deubiquitinase activity. This is likely to result in a partial dominant-negative effect of mutant ataxin 3 on beclin 1 levels, with similar consequences on this autophagy pathway as observed with mutant huntingtin fragments.
Apart from mutant huntingtin and ataxin 3, beclin 1 also interacted with atrophin 1 and the androgen receptor (Extended Data Fig. 10a, b ), which are mutated in the polyQ diseases dentatorubral-pallidoluysian atrophy (DRPLA) and spinal and bulbar muscular atrophy, respectively. PolyQ-expanded atrophin 1 and androgen receptor showed increased interactions with beclin 1 that elevated beclin 1 K48-polyubiquitination (Extended Data Fig. 10a, b ). Finally, we observed decreased beclin 1 levels and impaired starvation-induced autophagy in fibroblasts derived from patients with DRPLA, SCA3 or Huntington's disease, compared to controls ( Fig. 4e -g, Extended Data Fig. 10c -g).
Our data reveal previously undescribed roles for polyQ tracts in health and disease. The wild-type ataxin 3 polyQ stretch is required for binding to beclin 1; binding enables deubiquitination of this key Empty Flag 
Figure 4 | Expanded polyQ tracts inhibit ataxin 3-beclin 1 interaction, decrease beclin 1 levels and impair starvation-induced autophagy. a, b, HeLa cells were transfected with indicated constructs for 24 h and immunoprecipitated for endogenous beclin 1. a, Cells treated for the last 6 h with proteasome inhibitor (MG132, 10 μ M) were analysed for beclin 1 ubiquitination and for beclin 1-bound polyQ using anti-GFP antibodies. b, Immunocomplexes were analysed for beclin 1-bound ataxin 3 using anti-Flag antibodies. The bound ataxin 3/beclin 1 ratio is shown at the top. c, d, Brain samples from wild-type (WT) mice and Huntington's disease (HD) model transgenic mice were analysed for beclin 1 (c) and LC3-II (d).
WT fed n = 7, HD fed n = 5, WT fasted n = 7, HD fasted n = 6; AU, arbitrary units. Extended statistical analysis in Supplementary Table 1 autophagy inducer 26 and protects it from proteasome-mediated degradation. Importantly, this wild-type polyQ-mediated interaction was competed for by diverse disease-associated proteins with polyQ expansion mutations. The observed defect in starvation-induced autophagy caused by mutant polyQ proteins may reflect a less obvious impairment of basal autophagy, which is magnified under starvation conditions. This deficit may contribute to late-onset polyQ diseases, in which a relatively subtle defect is tolerated for decades before disease onset, and in which the toxic mutant protein itself is an autophagy substrate.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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Reagents. The primary antibodies used in the study include rabbit anti-actin (A2066), mouse anti-Flag M2 (F3165) and mouse anti-tubulin (T9026) from Sigma; rabbit anti-LC3 (NB 100-2220) and rabbit anti-atrophin-1 (NB100-2336) from Novus Biologicals; mouse anti-HA.11 (MMS-101P) from Covance; mouse anti-p62 (610833) from BD Bioscience; rabbit anti-beclin 1 (3738), rabbit anti-VPS34 (4263), rabbit anti-K48 polyUb (8081) and rabbit anti-K63 polyUb (5621) from Cell Signalling; rabbit anti-GFP (ab6556) from Abcam; mouse anti-ataxin 3 (MAB5360) and mouse anti-polyglutamine (MAB1574) from Millipore; mouse anti-GFP (632375) from Clontech; mouse anti-androgen receptor (sc-7305) from Santa Cruz; anti-mouse (NA931V) and anti-rabbit (NA934V) horseradish peroxidise (HRP)-conjugated secondary antibodies from GE Healthcare; goat anti-rabbit 800CW secondary antibodies (926-32211) from LI-COR; and Alexa Fluor 555-(A21428) conjugated goat anti-rabbit secondary antibodies from Invitrogen/Life Technologies. The constructs that were used in this work consisted of: empty pEGFP, HA-Ub, pEGFP-Q35 and pEGFP-Q81 as The following constructs were provided by J. Lim (HA-tagged androgen receptor with 25Q or 120Q) and Z. Ignatova (EGFP-tagged atrophin-1 with 19Q or 71Q). Cell lines. Human cervical carcinoma (HeLa) cells and striatal neuronal cell lines derived from wild-type HTT Q7/Q7 and heterozygous HTT Q7/Q111 knock-in mice (Coriell Institute CH00097 and CH00096, respectively) were grown at 37 °C (for HeLa) and at 33 °C (for striatal cells) in DMEM (Sigma) supplemented with 10% FBS, 100 U ml -1 penicillin/streptomycin, 2 mM l-glutamine and 1 mM sodium pyruvate (basal medium) in 5% CO 2 . HeLa cells stably expressing GFP-LC3 and HeLa cells stably expressing the mTagRFP-mWasabi-LC3 reporter were cultured in basal medium supplemented with 500 μ g ml -1 G418 (Sigma). For creation of mTagRFP-mWasabi-LC3 stable cell lines, mTagRFP-mWasabi-LC3 (construct from J. Lin 33 ) was cloned into pIRESneo using EcoR1 and SacII sites. The construct was transfected into HeLa cells, and transfected cells were selected using G418. Single-cell clones were generated by fluorescence-activated cell sorting (FACS) and cell lines showing moderate expression were selected. mTagRFP-mWasabi-LC3 monitors autophagic flux, as mWasabi (green) fluorescence is quenched when autophagosomes are acidified following fusion with lysosomes. Stable inducible HEK293 cells expressing wild-type (Q23) or mutant (Q74) huntingtin (HTT) exon 1 were generated by cloning GFP-HTT (mutant or wild-type) from eGFP-C1 into pCDNA5/TO using Xba1 and ApaI restriction sites. These constructs were linearized with MfeI and transfected into T-Rex-293 cells (Thermo Fisher), which stably express the tetracycline repressor protein. Transfected cells were selected by addition of hygromycin. Single-cell clones were generated, which showed expression of GFP-HTT only in the presence of doxycycline, and to enable comparison, with similar levels of HTT expression. HeLa cells (source ATCC) and HEK293 cells (source ECACC) were authenticated by STR profiling and were routinely tested for mycoplasma contamination. In some experiments, cells were starved in Hanks balanced salt solution (HBSS) medium (Invitrogen) for 4 h with or without 400 nM of bafilomycin A1 (BafA1) (Sigma). BafA1 treatment alone was carried out sometimes for 16 h with 200 nM, as indicated in the legends. Cell transfection was performed with TransIT 2020 Mirus (for DNA) or Lipofectamine 2000 reagents (for siRNA) (Invitrogen), using the manufacturers' protocols. Final siRNA concentrations of 20-100 nM were used for silencing with two rounds of knockdown for 5 days. The following oligonucleotides (ON-TARGETplus SMARTpool, Dharmacon) were used for ataxin 3 depletion: oligo 05 (ACAGGAAGGUUAUUCUAUA), oligo 06 (a) (GGACAGAGUUCACAUCCAU), oligo 07 (b) (GCACUAAGUCGCCA AGAAA), oligo 08 (GCAGGGCUAUUCAGCUAAG); for beclin 1 depletion: oligo 05 (GAUACCGACUUGUUCCUUA), oligo 06 (GGAACUCACA GCUCCAUUA), oligo 07 (CUAAGGAGCUGCCGUUAUA), oligo 08 (GAGAG GAGCCAUUUAUUGA). Ataxin 3 depletion in mice. All studies and procedures were performed with project licences granted by the UK Home Office and with the approval of the University of Cambridge Committee for Animal Studies. C57BL/6J mice (Jackson Laboratories) were depleted of ataxin 3 in the liver using the ThermoFisher Invivofectamine 3.0 system. The siRNA duplex solution was prepared and diluted to 2.4 mg ml -1 according to the manufacturer's instructions. Preparation of the final injection solution was also in accordance with the Thermofisher protocol. Briefly, siRNA (control/scrambled siRNA 4457289; ataxin 3 siRNA 4457308) was mixed with the complexation buffer and then the Invivofectamine 3.0 reagent (IVF3005, ThermoFisher). The ataxin 3 siRNA was an Ambion pre-designed sequence: sense (5-3): GCAUCGACCAAAACUUAUUtt; antisense (5-3): AAUAAGUUUUGGUCGAUGCat. The solution was vortexed, incubated at 50 °C for 30 min and then diluted in PBS. The solution was stored at 4 °C and later up to 200 μ l was injected into the lateral caudal vein at a final concentration of 1 mg kg -1 . Mice were monitored for any adverse side effects briefly after injection with none observed. Mice used were female, weighing approximately 20 g at the age of 6 weeks. Mice were randomly selected for injection with control or targeting siRNA and were matched by weight. The knockdown was left for 5 days. On the fourth day, the mice were deprived of food for a total period of 24 h with free access to water throughout the procedure. Livers from these mice were dissected, homogenized and resuspended in tissue lysis buffer on ice (50 mM Tris pH 7.4, 0.5% Triton X-100 and protease inhibitor cocktail) and the supernatant was centrifuged twice. Proteins were resolved by SDS-PAGE for further analysis. The same control was loaded onto each gel and the samples were normalized to that same control on the same gel to allow comparison between multiple samples. The animal experiments did not involve behavioural testing but focused on biochemistry; therefore, the samples were not blinded at this stage as we wanted to be able to load the gels in a suitable order. Food deprivation in Huntington's disease model mice. We used HD-N171-82Q mice (B6C3F1/J-Tg(HD82Gln)81 Dbo/J, Jackson Laboratory). These mice carry an N-terminal fragment expressing the first 171 amino acids of human huntingtin with 82 glutamine repeats under the mouse prion promotor 34 . The Huntington's disease transgenic mice and non-transgenic littermates were males and females at the age of 6 weeks in the study. The mice fasted and were deprived of food for a total period of 48 h with free access to water throughout the procedure. After 22.5 h starvation, mice were given free access to food for 1.5 h followed by a second round of starvation for another 22.5 h. At the end of this period, the mice were killed by a schedule 1 method. The brain was collected and frozen for western blot analysis. The mice were weighed at every stage of this experiment in order to monitor weight loss. Half brain samples from starved and fed mice were dissected, homogenized and resuspended in tissue lysis buffer on ice (50 mM Tris pH 7.4, 0.5% Triton X-100 and protease inhibitor cocktail) and the supernatant was centrifuged twice. Proteins were resolved by SDS-PAGE for further analysis. Immunohistochemistry. Thirty-micrometre sections of brains derived from Huntington's disease transgenic young and adult mice (6 and 12 weeks old, respectively) were analysed for neuronal aggregates as described 35 . Sections were labelled with anti-huntingtin antibody (clone mEM48, Chemicon, MAB5374) by free-floating immunohistochemistry. Staining was performed by peroxidase labelling using Vectastain Avidin:Biotinylated enzyme complex (ABC) kit and visualized with DAB reagent (Vector Laboratories). Aggregates were counted in the motor cortex in three fields on at least three sections per animal at a magnification of × 100 (Zeiss Axioskop2, field diameter 0.2 mm) and analysed for the average of aggregates in brains from young and adult Huntington's disease transgenic mice. The observer was blinded to the identity of the samples. Analysis of patient cells. Primary fibroblasts from 9 controls and 13 patients with mutant polyQ diseases were grown at 37 °C in DMEM supplemented with 10% FBS, 100 U ml -1 penicillin/streptomycin, GlutaMAX 1:100 (35050061, ThermoFisher) and 1 mM sodium pyruvate (basal medium) under 5% CO 2 . In some experiments, cells were starved in HBSS medium for 4 h or treated for 4 h with 400 nM BafA1. The following patient fibroblasts were obtained from Coriell Biorepository, Coriell Institute for Medical Research: Huntington's disease (HD) (GM04285, GM04287, GM04476, GM04867), DRPLA (GM13716, GM13717), SCA3 (GM06151, GM06153) and SCA7 (GM03561). The following patient fibroblasts were provided by F.Sq. A program to collect biological specimens at the Mendel Institute of Human Genetics for research purposes, including skin biopsies to derive fibroblast cell lines, was approved by the Ethical Committee from Casa Sollievo della Sofferenza Foundation, section of Istituto Tumori Giovanni Paolo II in Bari. Informed consent was obtained from healthy control subjects and from patients with DRPLA (AT2140102) or Huntington's disease (HD 940-01, HD960-01) and from the legal representative of another patient with Huntington's disease (HD305-01). See Supplementary Table 2 for a list of patient fibroblasts, their catalogue numbers and the matching reference numbers in the paper. Isolation and culture of primary cortical neurons. Primary cortical neurons were isolated from C57BL/6 mouse (Jackson Laboratories) embryos at embryonic day (E)16.5 as previously described 32 . Briefly, embryo brains were harvested and placed in PBS/glucose where the meninges were removed and the cerebral cortices were dissected. After mechanical dissociation using sterile micropipette tips, dissociated neurons were resuspended in PBS/glucose and collected by centrifugation. Viable
Letter reSeArCH cells were seeded on poly-ornithine-coated 12-multiwell plates. Cells were cultured in neurobasal medium supplemented with 2 mM glutamine, 200 mM B27 supplement and 1% penicillin/streptomycin at 37 °C in a humidified incubator with 5% CO 2 . One half of the culture medium was changed every two days until treatment or infection. After 5 days of ex vivo culturing, differentiated neurons were infected with lentiviral particles. Lentivirus production and infection. Short hairpin RNA lentiviral particles were produced and transduced following The RNAi Consortium (TRC) protocols. shRNA containing pLKO.1 vectors targeting mouse Atxn3 were obtained from The RNAi Consortium (TRCN0000123959 and TRCN0000123961). Scramble shRNA was a gift from D. Sabatini (Addgene plasmid 1864) 36 . Briefly, HEK293T packaging cells growing in 10-cm dishes were transfected with a mix of 2.5 μ g packaging vector (psPAX2), 270 ng envelope vector (pMD2.G) and 2.7 μ g hairpin-pLKO.1 vector. TransIT-LT1 (Mirus) was used as transfection reagent. After transfection, cells were cultured in high-serum medium. Cell culture medium was collected 40 h later and replaced by high-serum medium; this step was repeated 2-3 times at intervals of 24 h. Virus preparations were then concentrated by centrifu gation at 30,000 r.p.m. for 90 min. Viral particles were added to primary cultured neurons and incubated overnight. After 24 h, medium was replaced by full medium and cells were incubated for 5 more days. For autophagy flux experiments, neurons were treated with 200 nM BafA1 in full medium for 16 h or starved in HBSS with 400 nM BafA1 for 4 h. Western blot analysis. Cells were lysed in lysis buffer (20 mM Tris-HCl, pH 6.8, 137 mM NaCl, 1 mM EGTA, 1% Triton X-100, 10% glycerol and protease inhibitors cocktail) and protein samples were boiled in Laemmli buffer for 5-7 min at 100 °C, separated by SDS-PAGE, transferred onto PVDF membranes, subjected to western blot analysis, and visualized using an ECL enhanced chemiluminescence detection kit (GE Healthcare), or with direct infrared fluorescence detection on an Odyssey Infrared Imaging System. Immunoprecipitation and ubiquitination assays. Cells were lysed with IP buffer (20 mM Tris-HCl, pH 7.2, 150 mM NaCl, 2 mM MgCl 2 , 0.5% NP-40 and protease inhibitors cocktail). For ubiquitination experiments, cells were treated with a proteasome inhibitor MG132 (10 μ M) in the last 6 h before lysis with the IP buffer supplemented with 1 mM PMSF and 10 mM iodoacetamide. Whole-cell lysates obtained by centrifugation were incubated with 2-5 μ g of antibody overnight at 4 °C followed by 2 h incubation with protein A sepharose beads (GE Healthcare). The immunocomplexes were then washed with IP buffer for three times and separated by SDS-PAGE for further western blotting assay. In-vitro deubiquitination assay. Ubiquitinated beclin 1 was purified from HeLa cells transfected with expression vectors for HA-Ub and Flag-beclin 1 for 24 h as previously described 37 . For the last 6 h, the cells were treated with a proteasome inhibitor MG132 (10 μ M) and a 10 μ M cell-permeable, non-selective DUB inhibitor PR616 (ab144641, Abcam). Ubiquitinated beclin 1 was purified from cell lysates with anti-Flag-affinity beads (Sigma, A2220) in Flag lysis buffer (20 mM Tris-HCl, pH 6.8, 137 mM NaCl, 1 mM EGTA, 1% Triton X-100, 1 mM DTT, 10% glycerol and protease inhibitors cocktail). After washing with the Flag-lysis buffer, the proteins were eluted with 3× Flag peptides (F4799, Sigma). Recombinant ataxin-3 Q22 and Flag-ataxin 3 Q22 C14A were expressed in HeLa cells and purified using Flag affinity beads and eluted with 3× Flag peptides. In the in vitro deubiquitination assay, ubiquitinated beclin 1 was incubated with recombinant ataxin 3 in the deubiquitination buffer (50 mM Tris-HCl (pH 8.8), 50 mM NaCl, 5% glycerol, 10 mM DTT, 1 mM EDTA) at 37 °C. Fluorescence microscopy. The cells were grown on coverslips and were fixed in 4% paraformaldehyde (for LC3-GFP) or methanol (for endogenous LC3, 1:150 Novus Biologicals) for 5 min and then permeabilized with 0.1% Triton X-100. For blocking and primary and secondary antibodies, 1% BSA in PBS was used. The staining of PtdIns3P was performed as described in ref. 38 . Briefly, cells were fixed in 2% paraformaldehyde and permeabilized with 20 μ M digitonin in buffer A (20 mM Pipes pH 6.8, 137 mM NaCl, 2.7 mM KCl). Then cells were blocked with buffer A supplemented with 5% (v/v) FBS and 50 mM NH 4 Cl. Anti-PtdIns3P antibodies from Echelon (for 1 h, 1:300) and secondary antibodies were applied in buffer A with 5% FBS. Cells were post-fixed for 5 min in 2% paraformaldehyde, washed with PBS containing 50 mM NH 4 Cl, washed once with water and then mounted with Mowiol. For WIPI2 staining, cells were grown on coverslips at 60% confluency and were incubated in EBSS for 1 h. Then cells in 1 ml EBSS were fixed by the addition of 1 ml 4% paraformaldehyde to a final concentration of 2% and incubated for 10 min at room temperature and then cells were permeabilized with 0.1% Triton X-100. 1% BSA PBS solution was used for blocking before adding primary antibody (mouse anti-WIPI2, 1:100 Abcam ab105459). A Zeiss LSM880 confocal microscope was used for fluorescent confocal analysis. All confocal images were taken with a 63× oil-immersion lens. Microscopy assays (for example, dot quantification) were performed by selecting fields based on nuclear and GFP staining (with the channel for the dots turned off)-thus the operator was blinded to the outcome of the experiment when selecting suitably similar fields to image for subsequent computerised analysis. ImageJ was used for the analysis (number of vesicles or puncta). For the analysis of WIPI2 puncta that involved different cell lines in different conditions, we used a custom-designed image-processing pipeline in ImageJ. First, an estimation of the cytoplasmic area was made by simultaneously expanding an area from each nuclear centroid, until a neighbouring expansion is detected. The resulting mask represents individual cells and was subsequently used to identify WIPI2 dots. Identification of the dots started by reducing cytoplasmic background signal through application of a Gaussian convolution filter. The resulting image was then binarized according to the Chow and Kaneko adaptive thresholding method. Subsequently, connected or clustered dots were separated using a classic watershed segmentation algorithm. Consecutive quantification and feature extraction were then performed on all dots that met set size parameters. Automated microscope counting of autolysosomes labelled with a pH-sensitive mTagRFP-mWasabi-LC3 was carried out using a Thermo Scientific Cellomics ArrayScan VTI HCS reader and the Spot Detector Bioapplication protocol, as described 20 . About 800 cells per condition were analysed. Addition of exogenous PtdIns3P to cells. PtdIns3P di-C16 and carrier (Echelon) were reconstituted in H 2 O:tert-BuOH (9:1) solution. After 1 min bath sonication, carrier and PtdIns3P di-C16 were combined at a 1:1 ratio for 10 min at room temperature. The mixture of PtdIns3P di-C16 and carrier were diluted in medium and used for 1-2 h incubations of cells. The final concentration used was 1 μ M. For the negative control, DMEM was combined with carrier only and added to the cells. Mass spectrometry. HeLa cells were transfected with Flag-beclin 1 and HA-Ub for 24 h and treated for the last 6 h with proteasome inhibitor (MG132 10 μ M), and Flag beclin 1 was immunoprecipitated for identification of putative sites of ubiquitination using mass spectrometry. Samples were resolved into a pre-cast 4-12% Bis-Tris polyacrylamide gel (Novex, Thermo Fisher Scientific). The lanes were excised and cut into three approximately equal chunks and the proteins reduced, alkylated and digested in-gel. The resulting tryptic peptides were analysed by LC-MSMS using a Q Exactive coupled to an RSLCnano3000 (Thermo Scientific). Raw files were processed in Proteome Discoverer 1.4 using Sequest to search a human Uniprot database (downloaded 03/06/14, 20,176 entries). GlyGly (K) was set as a variable modification and carbamidomethyl (C) as a fixed modification. Peptides were filtered to high confidence (0.01 false discovery rate, FDR) using Percolator. Structural analysis of polyQ binding to beclin 1. Glide software (Schrödinger, LLC) was used for studying potential ligand (polyQ7 stretch)-receptor (human beclin 1 ECD; pdb 4DDP, ref. 39) interactions. Protein and ligand preparation were performed first, followed by generation of possible ligand binding sites using site-map. A receptor grid was then generated for each of the putative binding sites and standard precision peptide (SP-peptide) docking was performed. Although several potential binding sites were found, docking scores for two of the sites were substantially higher than for the others. It should be noted that that binding sites surrounding the N-terminal helix of beclin 1 ECD (pdb 4DDP) were not considered, as the yeast Vps30-BARA domain structure (pdb 5DFZ, ref. 40) shows that this helix is likely to be out of place, being part of the coiled-coil domain (CCD) of beclin 1. Docking poses from the best sites were used to generate figures. Visualization and generation of graphic illustrations of the molecular models were performed using PyMOL (http://www.pymol.org). Statistics. Statistical analysis was done using Microsoft Excel and GraphPad Prism v5. For ANOVA analysis involving multiple sample comparisons, post testing was performed to discriminate significance relationships. For t-test analysis, one-tailed test were performed for independent samples, as indicated in the figure legends. Error bars shown in the figures are standard deviation (s.d.) or standard error (s.e.m.), as stated. Sample sizes were chosen on the basis of extensive experience with the assays we have performed. The experiments were appropriately randomized. Data availability. Gel source images are provided in Supplementary Fig. 1 Results are normalized to control cells (HBSS + BafA1). Mean ± s.e.m., n = 5 replicates from two independent cultures. Two-way ANOVA (NS, not significant). b, HeLa cells were transfected with different Atxn3 siRNAs or scrambled siRNA as a control. Ataxin 3 knockdown (KD) efficiency is presented as well as basal LC3-II levels. LC3-II levels in ataxin-3-depleted HeLa cells were normalized to control cells; n = 4 independent experiments. One-way ANOVA with post hoc Tukey's test. c, p62 levels in HeLa cells depleted of ataxin 3 by siRNA. p62 levels were normalized to control cells (n = 4 independent experiments, one-tailed paired t-test). d, HeLa cells stably expressing mTagRFP-mWasabi-LC3 reporter were transfected with either scrambled or Atxn3 siRNA and were analysed with the ThermoFisher cellomics system to assess the number of autophagosomes and autolysosomes in the cells. Results are mean number of autophagosomes or autolysosomes per cell ± s.e.m. in eight fields from a representative experiment out of three independent experiments (onetailed unpaired t-test). Representative images of the cells were taken by confocal microscopy (total 800 cells). Scale bars, 10 μ m. e, Control and ataxin 3 KD HeLa cells were starved (HBSS, 4 h) or kept in full medium. The number of PtdIns3P (PI3P) phospholipid dots was analysed by staining with anti-PtdIns3P antibody. Results are mean dots per cell ± s.d. from a representative experiment out of three independent experiments as well as representative confocal images of PtdIns3P dots (red) for each condition (n = 20 cells). Scale bars, 10 μ m. Two-way ANOVA (column factor siRNA P < 0.001, row factor starvation P < 0.01, interaction P < 0.05) with Bonferroni's post-test. * P < 0.05, * * P < 0.01, NS, not significant.
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Extended Data Figure 2 | Ataxin 3 regulates starvation-induced autophagy. a, b, HeLa cells stably expressing GFP-LC3 were treated with control or Atxn3 siRNA and incubated for 1 h with carrier alone or carrier with 1 μ M PtdIns3P phospholipid. Then, the control cells and ataxin 3 KD cells with the different treatments were shifted to starvation conditions (HBSS, 4 h) or kept in full medium. a, The number of LC3 dots was analysed for each of the conditions and presented as mean LC3 dots per cell ± s.e.m, determined from n = 5 fields from a single representative experiment out of three independent experiments. Two-way ANOVA (column factor siRNA P < 0.001, row factor starvation P < 0.05, interaction P value not significant (NS)) with Bonferroni's posttest: for basal condition, NS; for starvation, P < 0.001. b, Representative confocal images of LC3 dots (green) from the different treatments are presented for the starvation condition. For a and b, the total number of cells analysed in basal control, n = 25; basal KD, basal KD carrier, basal KD carrier PtdIns3P, n = 30; HBSS control, n = 34; HBSS KD, HBSS KD carrier PtdIns3P, n = 37; HBSS KD carrier, n = 32. Scale bars, 10 μ m. c, Number of dots of the endogenous PtdIns3P effector, WIPI2, in HeLa cells that were transfected with Flag-ataxin 3 or empty vector and starved (EBSS, 1 h) with or without the PtdIns3P inhibitor Wortmannin (Wm, 20 nM). Data are presented as means ± s.e.m. of the number of WIPI2 dots per cell determined from the total number of cells analysed using software described in Methods from a representative experiment out of two independent experiments. Confocal images of WIPI2 dots (green) from the different treatments are shown. Number of cells analysed and used for the s.e.m. in empty Flag, n = 47; Flag-ataxin 3, n = 45; Flag-ataxin 3/Wm, n = 37. Scale bars, 10 μ m. One-way ANOVA with post hoc Tukey's test. d-f, Mice were depleted of ataxin 3 in the liver by injection of Atxn3 siRNA or control/scrambled siRNA formulations into the lateral caudal vein. The knockdown was left for 5 days with fasting on the fourth day. Livers from these mice were dissected and homogenized and proteins were resolved by SDS-PAGE. d, Representative blots and in vivo ataxin 3 knockdown efficiency. For quantification of beclin 1 and LC3-II, see Fig. 1d , e. e, Quantification of p62 levels; f, quantification of LC3-I levels in each group of mice (control fed, n = 9; ataxin 3 KD fed, n = 6; control fasted, n = 8, ataxin 3 KD fasted, n = 6; a.u, arbitrary units). e, Two-way ANOVA (column factor siRNA P < 0.05, row factor fasting P < 0.05, interaction P < 0.05) with Bonferroni's post-test. For f, two-way ANOVA (column factor siRNA NS, row factor starvation P < 0.05, interaction NS) with Bonferroni's post-test (NS). This suggests no obvious difference in LC3-I levels between the control and ataxin-3 KD groups. * * P < 0.01, * * * P < 0.001.
Extended Data Figure 4 | Analysis of beclin 1 lysine 402 modification. a, b, HeLa cells were transfected with Flag-beclin 1 and HA-Ub for 24 h and treated for the last 6 h with MG132 (10 μ M). Flag-beclin 1 was immunoprecipitated for mass spectrometry analysis. Tryptic digests of ubiquitin-conjugated beclin 1 resulted in peptides that contain a ubiquitin remnant derived from the ubiquitin C terminus ('GG' motif). a, Identification of a putative site of ubiquitination in beclin 1. Top, MS-MS spectrum of the unmodified beclin 1 peptide spanning residues 401-416. Amino acids with corresponding y ions are shown in blue. Bottom, MS-MS spectrum of an ion with a mass 114 Da greater than the unmodified peptide. The matching y ions and presence of a modified b2 ion indicate -GG modification of lysine 402. b, MS-MS spectra filtered to high confidence covering 100% of the ubiquitin sequence. Tryptic peptide spanning residues 43-54 including lysine 48 was identified as the sole high-confidence peptide with a modification corresponding to a -GG motif and the MS-MS spectra of the peptide demonstrate fragments corresponding to a -GG modified lysine 48. c, Levels of Flag-beclin 1 and Flag-beclin 1 K402R in HeLa cells that were treated for the last 6 h with MG132 (10 μ M). Results normalized to control (Flag-beclin 1 WT). n = 3 replicates from two independent experiments. Two-way ANOVA (column factor K402R NS, row factor MG132 P < 0.001, interaction P < 0.05) with Bonferroni's post-test. d, HeLa cells were transfected with the indicated vectors for 24 h and shifted in the last 4 h to HBSS. Beclin 1 and LC3-II levels were analysed and results normalized to control (Flag-beclin 1 WT). For LC3-II levels, n = 3 independent experiments, two-way ANOVA (column factor ataxin 3 P < 0.05, row factor K402R mutation P < 0.01, interaction P < 0.01) with Bonferroni's post-test. For beclin 1 levels, n = 4 independent experiments, two-way ANOVA (column factor ataxin
